Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Frank J Beurskens, PhD, Rob N de Jong, PhD, Sandra Verploegen, PhD, Marleen Voorhorst, Kristin Strumane, PhD, Margaret A. Lindorfer, PhD, Ronald P. Taylor, PhD, Erica Ollmann Saphire, PhD, Dennis Burton, PhD, Janine Schuurman, PhD, Paul W.H.I. Parren, PhD

Blood (2013) 122 (21): 375.

https://doi.org/10.1182/blood.V122.21.375.375

Published: 2013

Journal Articles

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, P. Todd Stukenberg, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD, Jan G. J. van de Winkel, PhD

Blood (2008) 112 (11): 1577.

https://doi.org/10.1182/blood.V112.11.1577.1577

Published: 2008

Journal Articles

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Jan G. J. van de Winkel, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD

Blood (2008) 112 (11): 1578.

https://doi.org/10.1182/blood.V112.11.1578.1578

Published: 2008

Journal Articles

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

Frank J. Beurskens, Sigrid R. Ruuls, Patrick J. Engelberts, Tom Vink, Wendy J. Mackus, Jan G. J. van de Winkel, Paul W. H. I. Parren

Blood (2008) 112 (10): 4354–4355.

https://doi.org/10.1182/blood-2008-07-171082

Published: 2008

NARROW

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

Email alerts

ASH Publications

American Society of Hematology

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only